BIIBClinical Trials•globenewswire•September 4, 2025 at 11:00 AM

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sentiment:Positive (70)

Summary

(NASDAQ:BIIB) Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 4, 2025 by globenewswire